US Patent Issued to GlaxoSmithKline Biologicals on July 14 for "Mutated PGLB oligosaccharyltransferase enzymes" (Swiss, American Inventors)

ALEXANDRIA, Va., July 14 -- United States Patent no. 12,680,087, issued on July 14, was assigned to GlaxoSmithKline Biologicals SA (Rixensart, Belgium).

"Mutated PGLB oligosaccharyltransferase enzymes" was invented by Joel Melby (Collegeville, Pa.), Joel David Karpiak (Collegeville, Pa.), Stefan Jochen Kemmler (Schlieren, Switzerland), Deepak Rudrappa (Collegeville, Pa.) and Laura Elizabeth Yates (Schlieren, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides mutated PglB oligosaccharyltransferase enzymes, polynucleotides that encode the mutated PglB oligosaccharyltransferase enzymes, host cells capable of expressing the engineered PglB oligosaccharyltransferase enzymes...